Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
GRI BIO, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/25/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "A New Approach to Inflammatory Diseases NASDAQ: GRI"
08/23/2023 8-K Acquisition/merger/asset purchase announced
Docs: "GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "GRI Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases"
07/07/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
07/06/2023 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM",
"GRI Bio, Inc. Balance Sheets",
"REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM",
"MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS",
"UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS"
06/08/2023 EFFECT Form EFFECT - Notice of Effectiveness:
06/07/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/30/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/26/2023 ARS Form ARS - Annual Report to Security Holders:
05/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/26/2023 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "AMENDED AND RESTATED"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/27/2023 D Form D - Notice of Exempt Offering of Securities:
04/27/2023 8-K Quarterly results
04/27/2023 8-K Quarterly results
04/25/2023 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
04/25/2023 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
04/25/2023 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
04/21/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
04/21/2023 8-K Quarterly results
04/20/2023 8-K Quarterly results
04/05/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Vallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ET Over 90% of the shares voted to date have shown support “FOR” each of the five proposals, but additional votes are needed in order to close the proposed merger with GRI Bio"
04/04/2023 425 Form 425 - Prospectuses and communications, business combinations:
04/03/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/31/2023 8-K Other Events  Interactive Data
03/31/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/23/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/09/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/08/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/06/2023 S-4/A Form S-4/A - Registration of securities, business combinations: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy